Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.
about
Differentiating mTOR inhibitors in renal cell carcinomaStrategic applications of gene expression: from drug discovery/development to bedsidePharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risksTemsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.Efficacy and comparative effectiveness of sirolimus as an anticancer drug.Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinA Bayesian approach for population pharmacokinetic modelling of sirolimus.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies.A validated tumorgraft model reveals activity of dovitinib against renal cell carcinomaDifferential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimusRisk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitorsPI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.HtrA serine proteases as potential therapeutic targets in cancer.mTOR inhibitor-associated dermatologic and mucosal problems.Inhibitors of mTOR.Renal cell carcinoma: focus on safety and efficacy of temsirolimus.Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.Dermatological toxicity associated with targeted therapies in cancer: optimal management.A GPU-accelerated algorithm for biclustering analysis and detection of condition-dependent coexpression network modulesPopulation pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.Ultrahigh dimensional time course feature selection.Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
P2860
Q26860172-8FFF078E-531C-496E-BDD1-075AE826357CQ26864172-FBEA601A-C543-49F2-BF93-D35172868412Q30358123-D88AD1D1-188E-4E5C-9E5D-E999704C61A9Q33383550-563A9BDB-FA31-4055-A473-A60DB7E14E41Q34316147-7FE7C41C-7BBF-4EC5-8A9A-F4FAA56B5B50Q34767073-8B77A9B1-71AD-4BC4-B247-AC1CE8DF6B41Q34891527-1B79C952-8565-493D-8F1C-09829AF7FBB7Q35187824-CF83C85E-DD10-474B-A716-6B1F51A7B1E5Q35827802-4DF4F2B4-E7CE-4755-8EE2-B6E8E90CCF78Q35835983-5D18C4E9-4218-4BF3-866E-63FCEEA83B69Q36412663-86B921FD-7D55-44CD-A412-997AC80377C0Q36606040-343AE8C6-AD40-4710-A13C-C1A239BC674FQ36696454-BA9D9C56-78EA-4E39-AB68-ACF5D3FB87F8Q36959193-9AC750B0-9B42-4436-8CE1-81A6B76AA1C4Q37032524-CF822D42-EFC2-4378-AF4F-75D30503FAE4Q37515512-375A7A62-7C91-494A-B740-BB1773B88AADQ37710669-C8B8A4B7-E6B8-42B0-A338-3CE4AC8007ECQ37819463-5739E0FB-697F-4DA0-9FBF-9C3CB7DB19E4Q37828399-8E0318FB-11B8-484F-B1B7-1EE16E1688F6Q37846389-3EC3599D-4789-4674-8E48-1C4C5D9C2368Q38012000-1B3A8626-9DD7-43E2-8F1E-338816CAC283Q38239381-1D5EA8A1-22BC-4AF7-B85E-D2D42E2E245AQ38711228-F314FC6A-3EBF-48F1-9AD5-44A320BD6285Q38779903-B796192F-5371-4F1B-A5DA-F485D5D9C32AQ40059080-12B2BA8D-F65A-4743-BA71-648515B78F28Q40822011-AF01B9FF-D007-482C-B3B0-CF975CBB175EQ46968784-9895D84F-D7F6-4064-9587-FE3B70872BA2Q50907850-01BBEB22-3044-4EB7-8852-1DA7C500089E
P2860
Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Population pharmacokinetics of ...... ts with advanced renal cancer.
@ast
Population pharmacokinetics of ...... ts with advanced renal cancer.
@en
type
label
Population pharmacokinetics of ...... ts with advanced renal cancer.
@ast
Population pharmacokinetics of ...... ts with advanced renal cancer.
@en
prefLabel
Population pharmacokinetics of ...... ts with advanced renal cancer.
@ast
Population pharmacokinetics of ...... ts with advanced renal cancer.
@en
P2093
P1476
Population pharmacokinetics of ...... ts with advanced renal cancer.
@en
P2093
Andrew Dorner
Cathie Leister
Fred Immermann
Gregor Bender
Jennifer Stover
Joseph P Boni
Michael E Burczynski
Natalie Twine
Virginia Fitzpatrick
P356
10.1016/J.CLPT.2004.08.025
P407
P577
2005-01-01T00:00:00Z